Belite Bio jumps as Benchmark reiterates Buy ahead of Q2 tinlarebant NDA
Belite Bio shares rose 4.48% to $179.25 after Benchmark reiterated a Buy rating and highlighted a near-term FDA filing catalyst for tinlarebant in Stargardt disease. The note also pointed to Belite’s large cash and investments balance and expectations for upcoming Phase 3 DRAGON data detail. (ph.investing.com)
1) What’s moving BLTE today
Belite Bio (BLTE) is higher in Wednesday trading after a fresh analyst update from Benchmark kept a Buy rating and reinforced a $217 price target, emphasizing the upcoming U.S. regulatory filing window for tinlarebant and continued investor focus on the Phase 3 DRAGON program in Stargardt disease. (ph.investing.com)
2) The catalyst investors are trading
Benchmark highlighted a near-term catalyst path that includes a more detailed presentation of DRAGON Phase 3 results and a planned New Drug Application filing with the FDA in the second quarter of 2026, keeping attention on tinlarebant as Belite’s lead value driver. The firm reiterated that DRAGON met its primary efficacy endpoint, citing a 35.7% reduction in macular lesion growth rate versus placebo. (ph.investing.com)
3) Balance sheet and spending outlook
The note also stressed liquidity, citing $353 million in cash and $420 million in investments, and laid out management’s planned spend over the next four years to prepare for commercialization: $150 million for R&D and $250 million for sales and marketing. That combination of runway plus a defined launch budget is helping support risk-on positioning into the NDA timeline. (ph.investing.com)